Yanhu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yanhu Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Daxue Zhu
Lanzhou University Second Hospital Lanzhou People's Republic of China
1 shared publication - Fengguang Yang
The Orthopedics Department, The Second Hospital of Lanzhou University, 82 Cuiying Men, Lanzhou, 730000 Gansu Province, PR China; The Second Clinical Medical College, Lanzhou University, No. 222, Tianshui South Road, Chengguan District, Lanzhou, 730000 Gansu Province, China; Orthopaedics Key Laboratory of Gansu Province, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730000 Gansu Province, PR China
1 shared publication - Guangzhi Zhang
Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou 730030, China
1 shared publication - Jinglin Ma
Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou 730030, China
1 shared publication - Xuegang He
The Second Clinical Medical College, Lanzhou University, Lanzhou, China
1 shared publication - Xuewen Kang
Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou 730030, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (7) , 1139
The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential
S100A6, also known as calcyclin, is a low-molecular-weight Ca2+-binding protein from the S100 family that contains two EF-hands. S100A6 is expressed in a variety of mammalian cells and tissues. It is also expressed in lung, colorectal, pancreatic, and liver cancers, as well as other cancers such as melanoma. S100A6 has many molecular functions related to cell proliferation, the cell cycle, cell differentiation, and the cytoskeleton. It is not only involved in tumor invasion, proliferation, and migration, but also the pathogenesis of other non-neoplastic diseases. In this review, we focus on the molecular mechanisms and potential therapeutic targets of S100A6 in tumors, nervous system diseases, leukemia, endometriosis, cardiovascular disease, osteoarthritis, and other related diseases.
- 17 July 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (7) , 1139
Open AccessThe Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential
S100A6, also known as calcyclin, is a low-molecular-weight Ca2+-binding protein from the S100 family that contains two EF-hands. S100A6 is expressed in a variety of mammalian cells and tissues. It is also expressed in lung, colorectal, pancreatic, and liver cancers, as well as other cancers such as melanoma. S100A6 has many molecular functions related to cell proliferation, the cell cycle, cell differentiation, and the cytoskeleton. It is not only involved in tumor invasion, proliferation, and migration, but also the pathogenesis of other non-neoplastic diseases. In this review, we focus on the molecular mechanisms and potential therapeutic targets of S100A6 in tumors, nervous system diseases, leukemia, endometriosis, cardiovascular disease, osteoarthritis, and other related diseases.